Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.

TitleImpact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.
Publication TypeJournal Article
Year of Publication2017
AuthorsParker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA
JournalClin Infect Dis
Volume64
Issue11
Pagination1612-1614
Date Published2017 Jun 01
ISSN1537-6591
KeywordsAdult, Anti-HIV Agents, Dideoxynucleosides, Drug Combinations, Female, HIV Infections, HIV-1, Humans, Lamivudine, Male, Medication Adherence, RNA, Viral, Self Report, Tenofovir, Treatment Failure, Viral Load
Abstract

In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.

DOI10.1093/cid/cix176
Alternate JournalClin. Infect. Dis.
PubMed ID28329243
PubMed Central IDPMC5434358
Grant ListU01 AI069481 / AI / NIAID NIH HHS / United States
R01 AI042006 / AI / NIAID NIH HHS / United States
UM1 AI069412 / AI / NIAID NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States
UM1 AI069481 / AI / NIAID NIH HHS / United States
P30 AI060354 / AI / NIAID NIH HHS / United States
UM1 AI068636 / AI / NIAID NIH HHS / United States